The antiserum was produced against synthesized peptide derived from human BID around the phosphorylation site of Ser78. AA range:44-93

Phospho-BID (S78) Polyclonal Antibody detects endogenous levels of BID protein only when phosphorylated at S78.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):SEsQE

BID

BH3-interacting domain death agonist

BID ;
BH3-interacting domain death agonist ;
p22 BID ;
BID

This gene encodes a death agonist that heterodimerizes with either agonist BAX or antagonist BCL2. The encoded protein is a member of the BCL-2 family of cell death regulators. It is a mediator of mitochondrial damage induced by caspase-8 (CASP8) ; CASP8 cleaves this encoded protein , and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release. Multiple alternatively spliced transcript variants have been found , but the full-length nature of some variants has not been defined. [provided by RefSeq , Jul 2008] ,

Domain:Intact BH3 motif is required by BIK , BID , BAK , BAD and BAX for their pro-apoptotic activity and for their interaction with anti-apoptotic members of the Bcl-2 family. ,Function:The major proteolytic product p15 BID allows the release of cytochrome c (By similarity) . Isoform 1 , isoform 2 and isoform 4 induce ICE-like proteases and apoptosis. Isoform 3 does not induce apoptosis. Counters the protective effect of Bcl-2. ,PTM:Phosphorylated upon DNA damage , probably by ATM or ATR. ,PTM:TNF-alpha induces a caspase-mediated cleavage of p22 BID into a major p15 and minor p13 and p11 products. ,subcellular location:A significant proportion of isoform 2 localizes to mitochondria , it may be cleaved constitutively. ,subcellular location:Associated with the mitochondrial membrane. ,subcellular location:Translocates to mitochondria as an integral membrane protein. ,subcellular location:When uncleaved , it is predominantly cytoplasmic. ,subunit:Forms heterodimers either with the pro-apoptotic protein BAX or the anti-apoptotic protein Bcl-2. ,tissue specificity:Isoforms 2 and 3 are expressed in spleen , bone marrow , cerebral and cerebellar cortex. Isoform 2 is expressed in spleen , pancreas and placenta (at protein level) . Isoform 3 is expressed in lung , pancreas and spleen (at protein level) . Isoform 4 is expressed in lung and pancreas (at protein level) . ,

Cytoplasm . Mitochondrion membrane . Mitochondrion outer membrane . When uncleaved , it is predominantly cytoplasmic. .; [BH3-interacting domain death agonist p15]: Mitochondrion membrane . Translocates to mitochondria as an integral membrane protein. .; [BH3-interacting domain death agonist p13]: Mitochondrion membrane . Associated with the mitochondrial membrane. .; [Isoform 1]: Cytoplasm .; [Isoform 3]: Cytoplasm .; [Isoform 2]: Mitochondrion membrane . A significant proportion of isoform 2 localizes to mitochondria , it may be cleaved constitutively. .

>>Platinum drug resistance ;
>>Sphingolipid signaling pathway ;
>>p53 signaling pathway ;
>>Apoptosis ;
>>Apoptosis - multiple species ;
>>Necroptosis ;
>>Natural killer cell mediated cytotoxicity ;
>>Non-alcoholic fatty liver disease ;
>>Alzheimer disease ;
>>Amyotrophic lateral sclerosis ;
>>Pathways of neurodegeneration - multiple diseases ;
>>Tuberculosis ;
>>Hepatitis C ;
>>Hepatitis B ;
>>Measles ;
>>Human cytomegalovirus infection ;
>>Influenza A ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Herpes simplex virus 1 infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Pathways in cancer ;
>>Viral myocarditis ;
>>Lipid and atherosclerosis